Geneos Therapeutics announced that it has closed its Series A round raising $10.5 Million in financing. This funding will launch its operations as a standalone entity to develop the next generation of neoantigen-targeting cancer immunotherapies. Geneos, created as a spinout of Inovio Pharmaceuticals, Inc. will leverage a proven immunotherapy platform under an exclusive license from Inovio in the field of personalized treatments for cancer. Concurrently with the Series A financing, Dr. Niranjan Y. Sardesai resigned as Inovio COO and will dedicate all his efforts as Geneos' CEO.